News
Position ：
- Quick review of 2022 Drug Review Annual Report2023-11-15
- Aponermin for Injection approved for marketing by China NMPA2023-11-14
- Glofitamab Injection approved with conditions for marketing by China NMPA2023-11-14
- NMPA becomes the applicant for PIC/S2023-11-09
- Proton Therapy System Approved for Marketing2023-11-08
- Children's Zibei Xuanfei Syrup approved for marketing by China NMPA2023-11-08
- Tongluo Mingmu Capsules approved for marketing by China NMPA2023-10-31
- Magnetic Resonance Imaging System approved for marketing2023-10-31
- Recombinant Humanized Type III Collagen Solution for injection approved for marketing2023-10-25
- Deucravacitinib Tablets approved for marketing by China NMPA2023-10-24